BIODANE PHARMA A/S: Financial statements 2019
CVR: 28310102
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
BIODANE PHARMA A/S (CVR 28310102) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 1,508,453 and a net result of DKK 256,752 compared with DKK -467,077 the year before. That is an increase of 49.2% compared with the year before. Equity in the 2019 report amounted to DKK 1,658,980. The solvency ratio was 93.5%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 1,508,453
- Profit/Loss
- DKK 256,752
- Equity
- DKK 1,658,980
- Total Assets
- DKK 1,775,138
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 1.5 mio. | 257 t. | 1.7 mio. | 1 |
| 2018 | - | 1 mio. | -467 t. | 1.4 mio. | 1 |
| 2017 | - | 968 t. | 103 t. | 1.9 mio. | 1 |
| 2016 | - | 747 t. | 33 t. | 767 t. | 1 |
| 2015 | - | 438 t. | -253 t. | 734 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
BIODANE PHARMA A/S has published its annual report for 2018. Gross profit came to DKK 1,010,830, and the net result was DKK -467,077.
About BIODANE PHARMA A/S
BIODANE PHARMA A/S is a Danish company of the type Aktieselskab based in Gesten, founded in 2004. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The company was previously named BIODANE PHARMA ApS and BIOFIBER TØRRING ApS. The management consists of Gunner Kreutzer Jakobsen. The board consists of Peter Gæmelke (chair), Flemming Torben Heden Knudsen, Gunner Kreutzer Jakobsen and Rasmus Juhl Rasmussen. The company is owned by BIODAN A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 2,534,166 and a net result of DKK 182,862 compared with DKK 1,651,356 the year before. Equity in the 2025 report amounted to DKK 2,505,002.